ClinicalTrials.gg
RecruitingNCT05528900SEIPA-FPIESUpdated Sep 29, 2023

A Multicentre French Prospective Study of Children With Food Protein Induced Enterocolitis Syndrome in Its Acute Form

An interventional study of allergy test in Food Protein Induced Enterocolitis Syndrome (FPIES), sponsored by Fondation Lenval. Recruiting at 19 sites in France. Open to participants aged Up to 17 Years. Per ClinicalTrials.gov, last updated 2023-09-29.

Sponsored by Fondation Lenval · Not applicable, Interventional, and Diagnostic

From the registry’s dates

  • Primary completion was expected by Oct 2025, 1 year 1 month ago, but the record still lists the study as recruiting.
  • Started Mar 2023; still recruiting 3 years 7 months later.
Phase
Not applicable
Study type
Interventional
Enrollment
600
Allocation
Not applicable
Ages
Up to 17 Years
Sex
All
01

Study summary

Food protein induced enterocolitis syndrome (FPIES), is a non-IgE mediated food allergy (FA) which seems to expand, and occurring in infancy. This disease is usually unknown by clinicians. In 2017, an international workgroup of American Academy of Allergy, Asthma and Immunology published clinical criteria to specify the diagnosis. However, there is a lack of information in literature for describe the evolution and atypical phenotypes. In addition, no prospective French series has been published to date. The aim of the study is to collect clinical features and allergy testing of children who have acute form of FPIES at diagnosis and during evolution during three years

Read the detailed description

Food protein induced enterocolitis syndrome (FPIES), is a non-IgE mediated food allergy (FA) which seems to expand, and occurring in infancy. Prevalence of FPIES is unknown. In 2011, Katz published cumulative incidence of cow 'milk FPIES of 3 per 1000 new-borns, from prospective birth cohort in Israel.

The offending food depend on the country, probably in relation to eating habits.

Cow's milk (CM) is most commonly incriminated and can lead to a chronic digestive disease or in its acute form with potentially life-threatening vomiting/diarrhoea/dehydration, confusing with anaphylaxis. Rice and oat in US, or fish and egg in France are the solid food most often implicated.

This disease is usually unknown by clinicians. Its diagnostic is based on clinical history, and differential diagnosis elimination.

In 2017, an international workgroup of American Academy of Allergy, Asthma and Immunology published clinical criteria to specify the diagnosis and management. According to this last definition (JACI 2017), patient have to meet the major criterion and at least 3 minor criteria. Major criterion is vomiting in the 1- to 4-h period after ingestion of the suspect food and absence of classic IgE-mediated allergic skin or respiratory symptoms. Minor criteria are :

  1. A second (or more) episode of repetitive vomiting after eating the same suspect food,
  2. Repetitive vomiting episode 1-4 h after eating a different food
  3. Extreme lethargy with any suspected reaction
  4. Marked pallor with any suspected reaction
  5. Need for emergency department visit with any suspected reaction
  6. Need for intravenous fluid support with any suspected reaction
  7. Diarrhea in 24 h (usually 5-10 h)
  8. Hypotension
  9. Hypothermia Skin prick test et IgE antibody are negative except atypical FPIES. Acute management begins with clinical evaluation, then administer normal saline bolus quickly. Parenteral ondansetron can be used to stop vomiting. Nutritional management implicate elimination of the offending foods. Only the oral food challenge in hospital can be done to determine resolution of FPIES after a long time of no symptom.

The age of tolerance, depend of the food. The average age of acquiring tolerance for cow's milk changes in the literature, around 8-10 months in Korea, around 1 year in Israel, around 5 years in the United States. There is no data in France on the recovery age of CM-FPIES.

However, there is a lack of information in literature for describe the evolution and atypical phenotypes. In addition, no prospective French series has been published to date.

Our work is a national prospective study, which will collect news cases of acute FPIES diagnosis in sixteen French centres.

Main objective: To determine the rate of acquisition of tolerance by food at 1 year, 2 years, 3 years post inclusion.

Secondary objectives:

  • Description of a population of children with newly diagnosed FPIES. 2. Describe the rate of patients with FPIES progressing to IgE sensitization whatever the food at 1 year, 2 years, 3 years post inclusion.

    1. Determine per food the rate of FPIES patients evolving towards IgE sensitization at 1 year, 2 years, 3 years post inclusion.
    1. Describe the rate of patients with FPIES progressing to clinical symptoms of IgE-mediated allergy, whatever the food, at 1 year, 2 years, 3 years post inclusion.
    1. Determine, by food, the rate of FPIES evolving towards clinical symptoms of IgE-mediated allergy at 1 year, 2 years, 3 years post inclusion.
    1. Describe the rate of patients with multiple FPIES at each time point of the study.
    1. Describe at each time the rates of patients with personal atopic comorbidities.

The inclusion period will last three years, and the follow up of each patient will last three years.

Allergologist will see the patient at inclusion visit, then one time a year. If the patient does not acquire tolerance, an oral food challenge (OFC) in hospital will lead to answer.

The aim of our work will help allergologist to manage FPIES children, with French specificities in offending food, and tolerance.

02

Conditions studied

  • Food Protein Induced Enterocolitis Syndrome (FPIES)

Browse trials for

Keywords

  • Non IgE mediated food allergy
  • FPIES,
  • children
03

In context

Enterocolitis

21 studies on the registry are indexed under Enterocolitis; 3 are open to participants now.

This study's planned enrollment of 600 is above the median of 75 across 14 interventional studies indexed under Enterocolitis.

Browse Enterocolitis studies →

Lead sponsor

Fondation Lenval is the lead sponsor of 61 studies on the registry; 18 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
Up to 17 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • age from 0 to 17 years old,
  • seen in allergologist visit for acute FPIES, due to history of suggestive clinical symptoms, confirmed by the criteria published in 2017 in the JACI (Nowak-Wegrzyn et al, JACI 2017), or by an oral food challenge for diagnosis in the absence of the requested clinical criteria,
  • affiliated to social security (public healthcare system)
  • signed consent of one of the parents or the holder of parental authority

Exclusion criteria

Exclusion Criteria:

  • Associated pathology that may contraindicate OFC at the discretion of the investigating physician. In particular justifying permanent treatment with a beta-blocker or an angiotensin-converting enzyme inhibitor.
05

Study design

Phase
Not applicable
Primary purpose
Diagnostic
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
600 participants (estimated)

Study arms

  • Experimental
    FPEIS children

    Diagnostic Test: allergy test

Interventions

  • Diagnostic testallergy test

    allergy test are oral food challenge , prick test and IgE blood rate

06

What researchers measure

Primary outcomes

  1. tolerance acquisition

    The acquisition of tolerance will be defined by negative OFC or accidental intake of the food at home tolerated according to parents discussion

    Time frame: through study completion, an average of 6 years

Secondary outcomes

  1. population description

    The description of the population included will be made according to the clinical, the demographic data, the allergy tests, the history of the disease

    Time frame: through study completion, an average of 6 years

  2. IgE sensitization

    IgE sensitization is defined by the positivity of an immediate-read skin test (wheal of the prick test greater than half of the positive histamine control) and/or the presence of specific IgE antibody on a blood sample (≥0.35 kU/L).

    Time frame: at 1 year, 2 years, 3 years post inclusion

  3. food sensitization

    food sensitization is defined by the positivity of an immediate-read skin test (wheal of the prick test greater than half of the positive histamine control)

    Time frame: at 1 year, 2 years, 3 years post inclusion

  4. IgE-mediated allergy

    IgE-mediated allergy is defined by the demonstration of clinical symptoms related to the presence of these specific IgEs.

    Time frame: at 1 year, 2 years, 3 years post inclusion

  5. IgE-dependent allergy

    IgE-dependent allergy will be defined by the appearance of symptoms a few minutes to 2 hours after ingestion of the food, with skin signs (urticaria, angioedema) and/or respiratory symptoms (dyspnea, laryngospasm, cough, bronchospasm ); digestive and neurological signs being potentially common with the diagnosis of FPIES

    Time frame: at 1 year, 2 years, 3 years post inclusion

  6. multiple FPIES

    A multiple FPIES will be defined by the presence of clinical symptoms of FPIES for at least two different foods

    Time frame: at 1 year, 2 years, 3 years post inclusion

  7. Atopic comorbidities

    Atopic comorbidities will be defined by asthma, allergic rhinitis, atopic dermatitis, and eosinophilic esophagitis

    Time frame: at 1 year, 2 years, 3 years post inclusion

07

Study locations

12 of 19 sites recruiting
  • Chu Angers
    Angers, France
    Recruiting
    • ANNE HOPPE, MD · Contact
  • Chi Robert Ballanger
    Aulnay-sous-Bois, France
    Recruiting
    • ARIANNE NEMNI · Contact
  • Chu Clermont-Ferrand
    Clermont-Ferrand, France
    Recruiting
    • ELODIE MICHAUD · Contact
  • Hopital Civils de Colmar
    Colmar, France
    Recruiting
    • JESSICA LOGLI · Contact
  • Chu Grenoble
    Grenoble, France
    Not yet recruiting
    • VIRGINIE JUBIN · Contact
  • Ch Haguenau
    Haguenau, France
    Recruiting
    • CARINE FAVRE-METZ · Contact
  • Chr Lille Hopital Jeanne de Flandre
    Lille, France
    Recruiting
    • ANTOINE DESCHILDRE · Contact
  • Hopital Saint Vincent de Paul Ghicl
    Lille, France
    Not yet recruiting
    • NICOLAS KALACH · Contact
  • Hopital Civil de Lyon
    Lyon, France
    Recruiting
    • PRISCILLE BIERME · Contact
  • Chu Montpellier
    Montpellier, France
    Recruiting
    • DAVIDE CAIMMI · Contact
  • Chu Nancy
    Nancy, France
    Recruiting
    • AMANDINE DIVARET-CHAUVEAU · Contact
  • Cabinet Berlioz
    Nice, France
    Not yet recruiting
    • MICHELE BERLIOZ · Contact
  • Hôpitaux Pédiatriques de Nice CHU-Lenval
    Nice, France
    Recruiting
  • Aphp Armand Trousseau
    Paris, France
    Not yet recruiting
    • ANAIS LEMOINE · Contact
  • Hopital Ambroise Pare Aphp
    Paris, France
    Recruiting
    • GREGOIRE BENOIST · Contact
  • Hopital Necker Enfants Malades Aphp
    Paris, France
    Not yet recruiting
    • GUILLAUME LEZMI · Contact
  • Hopital Robert Debre Aphp
    Paris, France
    Not yet recruiting
    • FLORE AMAT · Contact
  • Chu Rouen
    Rouen, France
    Recruiting
    • LAURE COUDERC · Contact
  • Cabinet Chabbert
    Toulouse, France
    Not yet recruiting
    • ANNE CHABBERT · Contact
08

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Sep 29, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT05528900
Lead sponsor
Fondation Lenval
Responsible party
Sponsor
First posted
Sep 6, 2022
Start date
Mar 31, 2023
Primary completion
Oct 2025 (estimated)
Completion
Oct 2028 (estimated)
Last update
Sep 29, 2023

Study contacts

Sibylle BLANC, MD
Contact
blanc.si@pediatrie-chulenval-nice.fr
0492030841
Dominique Donzeau
Contact
donzeau.d@chu-nice.fr
0492034560

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion